(-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity

Kim,Sung   Ok; Kim,Mi  Ryeo

doi:10.3892/ijo.2012.1686

January 2013 Volume 42 Issue 1

Full Size Image

Cover Legend PDF

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January 2013 Volume 42 Issue 1

Full Size Image

Cover Legend PDF

Article

(-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity

Authors:
- Sung Ok Kim
- Mi Ryeo Kim
View Affiliations / Copyright

Affiliations: Department of Herbal Pharmacology of Oriental Medicine, College of Oriental Medicine and R&D Team for the New Drug of Oriental Medicine (BK21), Daegu Hanny University, Daegu 706-828, Republic of Korea
Pages: 349-358
|
Published online on: November 6, 2012

https://doi.org/10.3892/ijo.2012.1686
Expand metrics +

Abstract

The aim of the present study was to assess whether (-)-epigallocatechin 3-gallate (EGCG) via epigenetic modifications, regulates Raf kinase inhibitor protein (RKIP) expression and invasive metastatic activity in AsPC-1 pancreatic adenocarcinoma cells. Basal levels of RKIP were examined in various human pancreatic cancer cell lines and MTT assay was used to assess cell viability. AsPC-1 cells were treated with EGCG with/without trichostatin A (TSA), as the positive control, for 24 h. The levels of RKIP and histone H3 induction were analyzed by immunoblot analysis. In order to determine the role of RKIP induction in NF-κB translocation and invasive metastatic activity in AsPC-1 cells, we examined NF-κB translocation, invasive metastatic parameters by RT-PCR, metastasis-related proteins by western blot analysis and matrix metalloproteinase (MMP)-2 and -9 activity by gelatin zymography. To validate RKIP induction through the extracellular signal regulated kinase (ERK) pathway, the cells were treated with U0126, an ERK inhibitor. Our results showed that EGCG induced RKIP upregulation via the inhibition of histone deacetylase (HDAC) activity which increased histone H3 expression and inhibited Snail expression, NF-κB nuclear translocation, MMP-2 and -9 activity and Matrigel invasion in AsPC-1 cells. The expression of E-cadherin in the cells was upregulated. The phosphorylation of ERK was decreased by RKIP induction following EGCG treatment. Furthermore, our results confirmed that U0126 treatment repressed ERK phosphorylation and induced RKIP expression. Taken together, our results strongly suggest that EGCG regulates RKIP/ERK/NF-κB and/or RKIP/NF-κB/Snail and inhibits invasive metastasis in the AsPC-1 human pancreatic adenocarcinoma cell line.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2.	Korea Ministry of Health and Welfare: Annual report of cancer statistics in Korea in 2008. http://mw.go.kr. 2011
3.	Warshaw AL, Gu ZY, Wittenberg J and Waltman AC: Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg. 125:230–233. 1990. View Article : Google Scholar : PubMed/NCBI
4.	Whitcomb DC: Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 287:G315–G319. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Tang H, Park S, Sun SC, Trumbly R, Ren G, Tsung E and Yeung KC: RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex. FEBS Lett. 4:662–668. 2009.PubMed/NCBI
6.	Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM and Kolch W: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 20:3079–3085. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Barbera MJ, Puig I, Dominguez D, Julien-Grille S, Guaita-Esteruelas S, Peiró S, Baulida J, Francí C, Dedhar S, Larue L and García de Herreros A: Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene. 23:7345–7354. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Munshi HG and Stack MS: Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev. 25:45–56. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Gregory PD, Wagner K and Horz W: Histone acetylation and chromatin remodeling. Exp Cell Res. 265:195–202. 2001. View Article : Google Scholar : PubMed/NCBI
10.	Struhl K: Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12:599–606. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Gray SG and Teh BT: Histone acetylation/deacetylation and cancer: an ‘open’ and ‘shut’ case? Curr Mol Med. 1:401–429. 2001.
12.	Hayden MS and Ghosh S: Signaling to NF-κB. Genes Dev. 18:2195–2224. 2004.
13.	Choi KC, Jung MG, Lee YH, Yoon JC, Kwon SH, Kang HB, Kim MJ, Cha JH, Kim YJ, Jun WJ, Lee JM and Yoon HG: Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 69:583–592. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Thakur VS, Gupta K and Gupta S: Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol. 41:353–361. 2012.PubMed/NCBI
15.	Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE and Eckert RL: (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis. 32:1525–1532. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Li Y, Yuan YY, Meeran SM and Tollefsbol TO: Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol Cancer. 9:274–286. 2010.PubMed/NCBI
17.	Yun JM, Jialal I and Devaraj S: Effects of epigallocatechin gallate on regulatory T cell number and function in obese v. lean volunteers. Br J Nutr. 103:1771–1777. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Fang M, Chen D and Yang CS: Dietary polyphenols may affect DNA methylation. J Nutr. 137:223S–228S. 2007.PubMed/NCBI
19.	Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM and Kolch W: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 401:173–177. 1999. View Article : Google Scholar : PubMed/NCBI
20.	Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I and Yeung KC: Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 72:3091–3104. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Minn AJ, Bevilacqua E, Yun J and Rosner MR: Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle. 11:2452–2457. 2012. View Article : Google Scholar : PubMed/NCBI
22.	Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P, Terracciano LM and Lugli A: Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol. 42:1888–1896. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Hu CJ, Zhou L, Zhang J, Huang C and Zhang GM: Immunohistochemical detection of Raf kinase inhibitor protein in normal cervical tissue and cervical cancer tissue. J Int Med Res. 39:229–237. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Zebisch A, Wölfler A, Fried I, Wolf O, Lind K, Bodner C, Haller M, Drasche A, Pirkebner D, Matallanas D, Rath O, Blyth K, Delwel R, Taskesen E, Quehenberger F, Kolch W, Troppmair J and Sill H: Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Leukemia. 26:1842–1849. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Wu K and Bonavida B: The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol. 29:241–254. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W and Sedivy JM: Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 21:7207–7217. 2001. View Article : Google Scholar : PubMed/NCBI
27.	Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 18:621–663. 2000.PubMed/NCBI
28.	Emonds E, Fitzner B and Jaster R: Molecular determinants of the antitumor effects of trichostatin A in pancreatic cancer cells. World J Gastroenterol. 16:1970–1978. 2010. View Article : Google Scholar : PubMed/NCBI
29.	Farrow B, Rychahou P, O’Connor KL and Evers BM: Butyrate inhibits pancreatic cancer invasion. J Gastrointest Surg. 7:864–870. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Hardtner C, Multhoff G, Falk W and Radons J: (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol. 684:36–43. 2012. View Article : Google Scholar
31.	Choi KC, Lee YH, Jung MG, Kwon SH, Kim MJ, Jun WJ, Lee J, Lee JM and Yoon HG: Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol Cancer Res. 7:2011–2021. 2009. View Article : Google Scholar
32.	Zucker S, Cao J and Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 19:6642–6650. 2000. View Article : Google Scholar : PubMed/NCBI
33.	Mook OR, Frederiks WM and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
34.	Duffy MJ, Maguire TM, Hill A, McDermott E and O’Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2:252–257. 2000. View Article : Google Scholar : PubMed/NCBI
35.	Vihinen P, Ala-aho R and Kähäri VM: Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 5:203–220. 2005. View Article : Google Scholar : PubMed/NCBI
36.	Gibbs DF, Warner RL, Weiss SJ, Johnson KJ and Varani J: Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol. 20:1136–1144. 1999. View Article : Google Scholar : PubMed/NCBI
37.	Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R and Nagayama M: Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol. 37:65–71. 2001. View Article : Google Scholar : PubMed/NCBI
38.	Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J and García De Herreros A: The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumor cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
39.	Jiao W, Miyazaki K and Kitajima Y: Inverse correlation of E-cadherin and Snail expression in hepatocellular cell lines in vitro and in vivo. Br J Cancer. 86:98–101. 2002. View Article : Google Scholar : PubMed/NCBI
40.	Poser I, Domínguez D, de Herreros AG, Varnai A, Buettner R and Bosserhoff AK: Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repression Snail. J Biol Chem. 276:24661–24666. 2001. View Article : Google Scholar : PubMed/NCBI
41.	Luo J, Lubaroff DM and Hendrix MJ: Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res. 59:3552–3556. 1999.PubMed/NCBI
42.	Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M and Mori T: Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 53:1696–1701. 1993.PubMed/NCBI
43.	Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE and Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55:5195–5199. 1995.PubMed/NCBI
44.	Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K and Bonavida B: Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 91:169–200. 2004. View Article : Google Scholar : PubMed/NCBI
45.	Eckel F, Schneider G and Schmid RM: Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs. 15:1395–1410. 2006. View Article : Google Scholar : PubMed/NCBI
46.	Schneider G, Siveke JT, Eckel F and Schmid RM: Pancreatic cancer: basic and clinical aspects. Gastroenterology. 128:1606–1625. 2005. View Article : Google Scholar : PubMed/NCBI
47.	Escara-Wilke J, Yeung K and Keller ET: Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev. Jun 9–2012.(Epub ahead of print).
48.	Klysik J, Theroux SJ, Sedivy JM, Moffit JS and Boekelheide K: Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal. 20:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
49.	Zeng L, Imamoto A and Rosner MR: Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets. 12:1275–1287. 2008. View Article : Google Scholar : PubMed/NCBI
50.	Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W and Yeung KC: Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene. 27:2243–2248. 2008. View Article : Google Scholar : PubMed/NCBI
51.	Fujimori Y, Inokuchi M, Takagi Y, Kato K, Kojima K and Sugihara K: Prognostic value of RKIP and p-ERK in gastric cancer. J Exp Clin Cancer Res. 31:30–38. 2012. View Article : Google Scholar : PubMed/NCBI
52.	Hazgui S, Bonnomet A, Nawrocki-Raby B, Milliot M, Terryn C, Cutrona J, Polette M, Birembaut P and Zahm JM: Epigallocatechin-3-gallate (EGCG) inhibits the migratory behavior of tumor bronchial epithelial cells. Respir Res. 9:33–46. 2008. View Article : Google Scholar : PubMed/NCBI
53.	Shankar S, Ganapathy S, Hingorani SR and Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci. 13:440–452. 2008. View Article : Google Scholar : PubMed/NCBI
54.	Takada Y, Andreeff M and Aggarwal BB: Indole-3-carbinol suppresses NF-κB and IκBα kinase activation, causing inhibition of expression of NF-κB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood. 106:641–649. 2005.
55.	Jin H, Yu Y, Zhang T, Zhou X, Zhou J, Jia L, Wu Y, Zhou BP and Feng Y: Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer. 126:2102–2111. 2010.PubMed/NCBI
56.	Miyoshi A, Kitajima Y, Kido S, Shimonishi T, Matsuyama S, Kitahara K and Miyazaki K: Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br J Cancer. 92:252–258. 2005.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

(-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles